See more : Telefonaktiebolaget LM Ericsson (publ) (ERIC-A.ST) Income Statement Analysis – Financial Results
Complete financial analysis of CareDx, Inc (CDNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CareDx, Inc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- U.S. Physical Therapy, Inc. (USPH) Income Statement Analysis – Financial Results
- FTAC Emerald Acquisition Corp. (EMLD) Income Statement Analysis – Financial Results
- Case Group AB (publ) (CASE.ST) Income Statement Analysis – Financial Results
- Far East Hotels and Entertainment Limited (0037.HK) Income Statement Analysis – Financial Results
- Kaddy Limited (KDY.AX) Income Statement Analysis – Financial Results
CareDx, Inc (CDNA)
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 280.32M | 321.79M | 296.40M | 192.19M | 127.07M | 76.57M | 48.32M | 40.63M | 28.14M | 27.31M | 22.10M | 20.45M |
| Cost of Revenue | 102.00M | 112.21M | 97.39M | 63.12M | 45.46M | 32.99M | 21.37M | 21.12M | 10.27M | 8.54M | 9.08M | 7.93M |
| Gross Profit | 178.33M | 209.58M | 199.01M | 129.08M | 81.61M | 43.58M | 26.95M | 19.51M | 17.87M | 18.77M | 13.02M | 12.52M |
| Gross Profit Ratio | 63.61% | 65.13% | 67.14% | 67.16% | 64.23% | 56.92% | 55.78% | 48.02% | 63.50% | 68.72% | 58.92% | 61.22% |
| Research & Development | 81.87M | 90.39M | 76.53M | 48.94M | 30.71M | 14.51M | 12.39M | 12.39M | 9.33M | 3.85M | 3.18M | 4.75M |
| General & Administrative | 117.87M | 100.40M | 74.96M | 48.81M | 36.54M | 21.96M | 18.91M | 20.73M | 12.25M | 8.44M | 4.81M | 4.69M |
| Selling & Marketing | 83.33M | 96.03M | 77.25M | 53.86M | 38.89M | 21.67M | 12.81M | 11.17M | 8.35M | 6.47M | 5.89M | 5.42M |
| SG&A | 201.20M | 196.42M | 152.21M | 102.66M | 75.43M | 43.63M | 31.72M | 31.89M | 20.60M | 14.91M | 10.70M | 10.11M |
| Other Expenses | 98.62M | -2.87M | -2.63M | -4.81M | -719.00K | -178.00K | -1.49M | -1.92M | -188.00K | 147.00K | -536.00K | -14.00K |
| Operating Expenses | 381.69M | 286.81M | 228.73M | 146.79M | 106.15M | 58.14M | 44.11M | 44.28M | 29.93M | 18.75M | 13.88M | 14.86M |
| Cost & Expenses | 483.69M | 399.02M | 326.12M | 209.91M | 151.60M | 91.13M | 65.48M | 65.40M | 40.20M | 27.30M | 22.96M | 22.79M |
| Interest Income | 11.87M | 3.76M | 160.00K | 271.00K | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 271.00K | 0.00 | 3.70M | 5.86M | 1.86M | 1.59M | 2.12M | 2.15M | 2.70M |
| Depreciation & Amortization | 19.82M | 16.01M | 11.89M | 9.54M | 5.52M | 4.22M | 3.76M | 2.92M | 796.00K | 512.00K | 663.00K | 1.07M |
| EBITDA | -89.66M | -61.22M | -17.84M | -10.21M | -19.01M | -11.36M | -14.61M | -17.85M | -11.26M | 523.00K | -194.00K | -1.27M |
| EBITDA Ratio | -31.98% | -24.03% | -10.06% | -8.44% | -19.56% | -19.25% | -38.59% | -65.68% | -43.29% | -4.50% | -0.88% | -6.21% |
| Operating Income | -203.36M | -77.23M | -29.73M | -17.72M | -24.53M | -15.58M | -20.29M | -37.33M | -11.93M | 1.25M | -857.00K | -2.34M |
| Operating Income Ratio | -72.55% | -24.00% | -10.03% | -9.22% | -19.31% | -20.35% | -42.00% | -91.88% | -42.40% | 4.58% | -3.88% | -11.45% |
| Total Other Income/Expenses | 13.22M | 997.00K | -2.36M | 2.78M | 585.00K | -32.64M | -36.98M | -4.03M | -1.78M | -1.97M | -2.69M | -2.72M |
| Income Before Tax | -190.14M | -76.23M | -32.09M | -19.75M | -23.95M | -48.22M | -57.27M | -41.36M | -13.71M | -719.00K | -3.54M | -5.06M |
| Income Before Tax Ratio | -67.83% | -23.69% | -10.83% | -10.28% | -18.85% | -62.97% | -118.51% | -101.80% | -48.70% | -2.63% | -16.03% | -24.74% |
| Income Tax Expense | 141.00K | 379.00K | -1.43M | -1.04M | -1.98M | -1.43M | -1.71M | -1.61M | 665.00K | -1.50M | 2.15M | 2.70M |
| Net Income | -190.28M | -76.61M | -30.66M | -18.71M | -21.97M | -46.76M | -55.47M | -39.47M | -13.71M | 781.00K | -3.54M | -5.06M |
| Net Income Ratio | -67.88% | -23.81% | -10.34% | -9.74% | -17.29% | -61.06% | -114.79% | -97.14% | -48.70% | 2.86% | -16.03% | -24.74% |
| EPS | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.13 | -0.48 | -0.69 |
| EPS Diluted | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.10 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.31M | 16.50M | 11.82M | 5.82M | 7.37M | 7.37M |
| Weighted Avg Shares Out (Dil) | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.33M | 16.50M | 11.86M | 9.28M | 7.37M | 7.37M |
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
How CareDx (CDNA) Stock Stands Out in a Strong Industry
CareDx Appoints Bryan Riggsbee to Its Board of Directors
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
CareDx Issues Statement in Patent Infringement Case
Source: https://incomestatements.info
Category: Stock Reports